CHINA NT PHARMA GROUP COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.021 HKD | -4.55% |
|
-8.70% | -61.82% |
| Mar. 28 | China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 15 | China NT Pharma Group Company Limited Announces Directorate Changes | CI |
| Sales 2021 | 227M 31.31M 245M | Sales 2022 | 207M 28.6M 224M | Capitalization | 151M 20.91M 164M |
|---|---|---|---|---|---|
| Net income 2021 | -150M -20.72M -162M | Net income 2022 | -66M -9.12M -71.4M | EV / Sales 2021 | 4.11 x |
| Net Debt 2021 | 823M 114M 890M | Net Debt 2022 | 821M 113M 888M | EV / Sales 2022 | 4.69 x |
| P/E ratio 2021 |
-0.73
x | P/E ratio 2022 |
-2.27
x | Employees | 16 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.55% | ||
| 1 week | -8.70% | ||
| Current month | -4.55% | ||
| 1 month | -40.00% | ||
| 3 months | -58.82% | ||
| 6 months | -73.75% | ||
| Current year | -61.82% |
1 week
0.02
0.02
1 month
0.020.04
Current year
0.020.06
1 year
0.020.10
3 years
0.020.43
5 years
0.021.07
10 years
0.023.24
| Managers | Title | Age | Since |
|---|---|---|---|
Tit Ng
CEO | Chief Executive Officer | 60 | 94-12-31 |
Jing Fang
DFI | Director of Finance/CFO | 55 | 19-05-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yu Biao Zhao
BRD | Director/Board Member | 54 | 19-12-30 |
Tit Ng
CEO | Chief Executive Officer | 60 | 94-12-31 |
Yu Chin
FOU | Founder | 60 | 94-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | -1.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.021 | -4.55% | 717,500 |
| 24-04-18 | 0.022 | +4.76% | 2,331,500 |
| 24-04-17 | 0.021 | -4.55% | 1,810,000 |
| 24-04-16 | 0.022 | 0.00% | 6,302,500 |
| 24-04-15 | 0.022 | 0.00% | 1,000 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
CHINA NT PHARMA GROUP COMPANY LIMITED is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -61.82% | 7.42M | |
| +20.91% | 43.54B | |
| +16.96% | 21.74B | |
| +9.05% | 13.53B | |
| +7.98% | 13.02B | |
| +33.80% | 11.28B | |
| -11.05% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +7.71% | 5.09B |
- Stock Market
- Equities
- 1011 Stock
